Population Pharmacokinetics of Antiepileptic Medications

Population pharmacokinetics examines the sources and extent of variability in drug concentration–time profiles among individuals receiving antiepileptic medications. By integrating patient characteristics—such as body weight, age, organ function and concurrent therapies—into mathematical models, researchers can predict how dosing regimens translate into plasma and tissue exposures across diverse patient groups. Nonlinear mixed-effects approaches allow estimation of typical pharmacokinetic parameters (clearance, volume of distribution, absorption rate) and their interindividual variability. Physiologically based pharmacokinetic models extend this framework by incorporating anatomical and biochemical information to simulate drug behaviour in special populations, including pregnant women, children and those with comorbidities. Such analyses underpin dose optimisation, therapeutic drug monitoring and risk mitigation of adverse events, informing personalised treatment strategies for epilepsy management worldwide.

Research from Nature Portfolio

Researchers have developed a population pharmacokinetic model for oxcarbazepine and its active metabolite, the monohydroxy derivative, by analysing sparse sampling data from adult patients with epilepsy. A one-compartment structure with first-order absorption adequately described metabolite concentration–time profiles, with body weight emerging as the principal covariate influencing clearance and distribution. Threshold values for trough concentration and area under the curve were identified to predict dose-related adverse events—dizziness, somnolence, headache and diplopia—thereby providing concrete targets for therapeutic drug monitoring. This model, derived from real-world clinical sampling, offers a robust basis for individualising oxcarbazepine therapy and minimising toxicity.

Population Pharmacokinetics of Antiepileptic Medications publication trend

The graph below shows the total number of articles in population pharmacokinetics of antiepileptic medications across all publications each year (not limited to Nature Index journals).

Technical terms

Population pharmacokinetics: Study of variability in drug concentration–time profiles within a patient population, accounting for demographic and physiological covariates.

Nonlinear mixed-effects modelling: Statistical framework that estimates typical pharmacokinetic parameters and quantifies interindividual variability using both fixed and random effects.

Physiologically based pharmacokinetic modelling: Mechanistic approach that employs anatomical, physiological and biochemical data to simulate drug absorption, distribution, metabolism and excretion in the body.

Area under the curve (AUC): Integral of the plasma concentration–time profile, representing total drug exposure over a dosing interval.

Trough concentration: Lowest drug concentration measured immediately before the next dose, used as a marker to guide dose adjustments.

Monohydroxy derivative (MHD): Primary active metabolite of oxcarbazepine responsible for the majority of its anticonvulsant activity.

References

1. Chronic Treatment with Oxcarbazepine Attenuates Its Anticonvulsant Effect in the Maximal Electroshock Model in Mice. International Journal of Molecular Sciences (2024).
2. Application of Physiologically Based Pharmacokinetic Modeling to Predict Maternal Pharmacokinetics and Fetal Exposure to Oxcarbazepine. Pharmaceutics (2022).
3. Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy. Scientific Reports (2021).